Recent Bladder Cancer News

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer

(April 3, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder)... Continue Reading


Keytruda Improves Survival of Advanced Bladder Cancer

(February 26, 2018)

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of... Continue Reading


Avelumab Immunotherapy Approved for Bladder Cancer

(May 15, 2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed... Continue Reading


FDA Approves Imfinzi for Treatment of Urothelial Cancer

(May 11, 2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease... Continue Reading


FDA Approves Opdivo for Treatment of Bladder Cancer

(February 16, 2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a... Continue Reading


Tecentriq® Approved for Bladder Cancer

(June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor,... Continue Reading


Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer

(June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy.... Continue Reading


Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

(March 14, 2016)

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy... Continue Reading


Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer

(January 21, 2016)

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently... Continue Reading


Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer

(March 31, 2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at... Continue Reading


Next Page »